SEONGNAM-SI, South Korea--(BUSINESS WIRE)--AriBio Co., Ltd. (AriBio), announces signing of exclusive marketing rights for AR1001, an investigational drug for early Alzheimer’s disease, in China for up to $770 million USD.

韩国城南寺——（商业新闻短讯）——AriBio有限公司（AriBio）宣布以高达7.7亿美元的价格在中国签署AR1001（一种治疗早期阿尔茨海默病的研究药物）的独家销售权。

The term consists of a non-refundable upfront payment of 120 billion KRW (approximately 90 million USD), with the total deal summing up to 5.59 billion RMB (approximately 770 million USD) inclusive of milestone payments with additional royalties. The upfront payment will be paid starting from mid-2024..

该条款包括不可退还的1200亿韩元（约9000万美元）的预付款，总交易金额为55.9亿元人民币（约7.7亿美元），包括里程碑付款和额外的版税。预付款将从2024年年中开始支付。

In response to the increasing Alzheimer’s disease population in China, prominent pharmaceutical companies have sought to develop safe and effective oral treatments for Alzheimer’s disease. To date, AriBio has partnered for exclusive marketing rights in South Korea with Samjin Pharmaceutical for 100 billion KRW.

为了应对中国阿尔茨海默氏病人口的增加，知名制药公司寻求开发安全有效的阿尔茨海默氏病口服治疗方法。迄今为止，AriBio已与Samjin Pharmaceutical以1000亿韩元的价格在韩国取得独家营销权。

And now, the partnership has expanded to China, cumulating to 1.12 trillion KRW (approximately 840 million USD). Considering the market competition for Alzheimer’s drugs in China and the sales strategy, the licensee requested not to be disclosed until an agreed upon time..

现在，合作伙伴关系已扩展到中国，累计达到1.12万亿韩元（约8.4亿美元）。考虑到中国阿尔茨海默氏病药物的市场竞争和销售策略，被许可人要求在商定的时间之前不要披露。

The global Phase 3 clinical trial for AR1001 in early Alzheimer’s disease patients (Polaris-AD) is on-going in the United States, United Kingdom, and South Korea. Furthermore, the clinical trial is awaiting regulatory approval in China and the European Union. This study will be conducted across 180 global sites.

AR1001在早期阿尔茨海默病患者（Polaris AD）中的全球3期临床试验正在美国，英国和韩国进行。此外，该临床试验正在等待中国和欧盟的监管部门批准。这项研究将在全球180个地点进行。

The first patient enrollment began in the United States in December 2022, and the rest of the regions are actively enrolling..

2022年12月，美国开始了第一次患者登记，其余地区正在积极登记。

Matthew (Jai Jun) Choung, CEO and Chairman of AriBio, stated, “This deal demonstrates our unwavering commitment to developing meaningful treatments for Alzheimer’s disease, and our partners will help position AR1001 for success in the major Asian territories. We are building momentum in our AR1001 program, as we continue to discuss with other potential partners in Asian countries, the Middle East, South America, as well as Europe and the United States.”.

AriBio首席执行官兼董事长Matthew（Jai Jun）Choung表示：“这项交易表明我们坚定不移地致力于开发有意义的阿尔茨海默病治疗方法，我们的合作伙伴将帮助AR1001在亚洲主要地区取得成功。我们正在为AR1001计划建立势头，同时我们将继续与亚洲国家、中东、南美以及欧洲和美国的其他潜在合作伙伴进行讨论。”

About AR1001

关于AR1001

AR1001 is a PDE5 inhibitor being developed as an investigational oral agent for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 has also demonstrated robust reduction of hyperphosphorylated tau proteins in pre-clinical models as well as in a Phase 2 trial..

AR1001是一种PDE5抑制剂，正在开发作为治疗阿尔茨海默病的研究性口服药物。临床前研究通过抑制神经元凋亡和恢复突触可塑性证实了AR1001的神经保护作用。AR1001还在临床前模型和2期试验中证明了过度磷酸化tau蛋白的强烈减少。

About AR1001-ADP3-US01

关于AR1001-ADP3-US01

AR1001-ADP3-US01 (NCT05531526) is a Phase 3 double-blind, randomized, placebo-controlled, multi-center trial to evaluate the efficacy and safety of AR1001 over 52 weeks in participants with early Alzheimer’s disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer’s disease through various cognitive and functional assessments.

AR1001-ADP3-US01（NCT05531526）是一项3期双盲，随机，安慰剂对照，多中心试验，用于评估AR1001在52周内对早期阿尔茨海默病参与者的疗效和安全性。该研究旨在通过各种认知和功能评估来评估AR1001在减缓阿尔茨海默病进展方面的有效性和安全性。

The details of the clinical trial are available at ClinicalTrials.gov..

临床试验的详细信息可在ClinicalTrials.gov上获得。

About AriBio

关于AriBio

AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in both South Korea and the United States. The company focuses on the development of novel therapies for neurodegenerative diseases. The company continues to expand its partnerships to accelerate the development of meaningful treatment options for neurodegenerative diseases..

AriBio Co.，Ltd.是一家总部位于韩国的生物制药公司，在韩国和美国均设有办事处。该公司专注于开发神经退行性疾病的新型疗法。该公司继续扩大合作伙伴关系，以加速开发有意义的神经退行性疾病治疗方案。